Submission of Monitoring Agency report for the period ended 30th September. 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aptus Pharma Limited submitted its first Monitoring Agency Report for the IPO proceeds to BSE, prepared by CARE Ratings Limited. The company raised Rs. 13.02 crore through an SME IPO held from September 23 to September 25, 2025, of which Rs. 12.94 crore was received in the public issue account. The report confirms nil deviation in the use of proceeds, but no utilization has actually started yet — the full Rs. 13.02 crore remains unutilized as of September 30, 2025, and is parked in the public issue account with ICICI Bank. The planned deployment includes Rs. 1.63 crore for office premises and industrial racks, Rs. 8.00 crore for working capital, Rs. 1.91 crore for general corporate purposes, and Rs. 1.48 crore for offer expenses, all targeted for completion by March 2026. The Chartered Accountant certificate supporting the report was issued by A B K B & Co. on October 29, 2025.
This is a routine post-IPO compliance filing with no negative findings, which is a neutral-to-mildly positive signal for shareholders. However, zero utilization in the first quarter after listing means investors will need to watch for timely deployment of IPO funds into the stated objects by the March 2026 deadline to ensure the company executes its growth plan.